Blepharitis-Pipeline Review, H1 2016

Blepharitis-Pipeline Review, H1 2016

  • Products Id :- GMDHC7798IDB
  • |
  • Pages: 44
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary


Global Markets Direct's, 'Blepharitis-Pipeline Review, H1 2016', provides an overview of the Blepharitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Blepharitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Blepharitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Blepharitis

The report reviews pipeline therapeutics for Blepharitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Blepharitis therapeutics and enlists all their major and minor projects

The report assesses Blepharitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Blepharitis

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Blepharitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Blepharitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Blepharitis Overview 6

Therapeutics Development 7

Pipeline Products for Blepharitis-Overview 7

Blepharitis-Therapeutics under Development by Companies 8

Blepharitis-Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Early Stage Products 11

Blepharitis-Products under Development by Companies 12

Blepharitis-Companies Involved in Therapeutics Development 13

Allergan Plc 13

InSite Vision Incorporated 14

Kala Pharmaceuticals, Inc. 15

NicOx S.A. 16

Senju Pharmaceutical Co., Ltd. 17

Blepharitis-Therapeutics Assessment 18

Assessment by Monotherapy Products 18

Assessment by Target 19

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Drug Profiles 27

AGN-195263-Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

azithromycin-Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

dexamethasone acetate-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

fluticasone propionate-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

ISV-405-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

loteprednol etabonate-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Qi-305-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Blepharitis-Recent Pipeline Updates 35

Blepharitis-Dormant Projects 40

Blepharitis-Product Development Milestones 41

Featured News & Press Releases 41

Jul 08, 2014: InSite Vision Plans to Submit New Drug Application to FDA for DexaSite for the Treatment of Blepharitis in Adults 41

Nov 12, 2013: Kala Pharmaceuticals Presents Preclinical Data on Mucus Penetrating Particles at 2013 AAPS Annual Meeting and Exposition 41

Appendix 43

Methodology 43

Coverage 43

Secondary Research 43

Primary Research 43

Expert Panel Validation 43

Contact Us 43

Disclaimer 44

List of Figures

Number of Products under Development for Blepharitis, H1 2016 7

Number of Products under Development by Companies, H1 2016 8

Comparative Analysis by Clinical Stage Development, H1 2016 10

Assessment by Monotherapy Products, H1 2016 18

Number of Products by Targets, H1 2016 19

Number of Products by Stage and Targets, H1 2016 19

Number of Products by Mechanism of Actions, H1 2016 21

Number of Products by Stage and Mechanism of Actions, H1 2016 21

Number of Products by Routes of Administration, H1 2016 23

Number of Products by Stage and Routes of Administration, H1 2016 23

Number of Products by Molecule Types, H1 2016 25

Number of Products by Stage and Molecule Types, H1 2016 25

List of Tables

Number of Products under Development for Blepharitis, H1 2016 7

Number of Products under Development by Companies, H1 2016 8

Comparative Analysis by Late Stage Development, H1 2016 9

Comparative Analysis by Clinical Stage Development, H1 2016 10

Comparative Analysis by Early Stage Development, H1 2016 11

Products under Development by Companies, H1 2016 12

Blepharitis-Pipeline by Allergan Plc, H1 2016 13

Blepharitis-Pipeline by InSite Vision Incorporated, H1 2016 14

Blepharitis-Pipeline by Kala Pharmaceuticals, Inc., H1 2016 15

Blepharitis-Pipeline by NicOx S.A., H1 2016 16

Blepharitis-Pipeline by Senju Pharmaceutical Co., Ltd., H1 2016 17

Assessment by Monotherapy Products, H1 2016 18

Number of Products by Stage and Target, H1 2016 20

Number of Products by Stage and Mechanism of Action, H1 2016 22

Number of Products by Stage and Route of Administration, H1 2016 24

Number of Products by Stage and Molecule Type, H1 2016 26

Blepharitis Therapeutics-Recent Pipeline Updates, H1 2016 35

Blepharitis-Dormant Projects, H1 2016 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Allergan Plc

InSite Vision Incorporated

Kala Pharmaceuticals, Inc.

NicOx S.A.

Senju Pharmaceutical Co., Ltd.

Blepharitis Therapeutic Products under Development, Key Players in Blepharitis Therapeutics, Blepharitis Pipeline Overview, Blepharitis Pipeline, Blepharitis Pipeline Assessment

select a license
Single User License
USD 2000 INR 143800
Site License
USD 4000 INR 287600
Corporate User License
USD 6000 INR 431400



I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]